Boom Capital Ventures

Olio Labs is a biotechnology company focused on developing combination therapeutics that leverage artificial intelligence to enhance treatment efficacy and reduce side effects. By employing automated discovery methods, the company analyzes protein interactions in the body, allowing for a more comprehensive approach to therapeutic design. Unlike traditional methods that typically target a limited number of proteins, Olio Labs' innovative strategy aims to create effective treatment solutions that consider a wider range of interacting proteins, ultimately improving patient outcomes.

Bioptimus is a biotechnology company focused on developing a universal artificial intelligence foundation model that integrates various scales of biology, from molecules to cells, tissues, and entire organisms. The company's innovative technology leverages generative AI to transform complex multiscale biological data into actionable insights, facilitating significant advancements in scientific research and biomedical innovation. By enabling clients to effectively harness this data, Bioptimus aims to drive breakthrough discoveries and enhance the efficiency of biotechnological processes.

Nabla Bio is a biotechnology company that specializes in the development of an autoreverse platform for the discovery of innovative protein variants. These proteins, which exhibit unique qualities, are engineered to create new medicines and enhance nutritional products. By leveraging insights gained from billions of natural proteins, Nabla Bio enhances these variants through extensive experimentation, allowing for advanced applications in both medical and industrial fields. The company's focus on complex measurements of protein function positions it as a leader in the pursuit of previously unattainable protein capabilities.

BioLoomics, Inc. is a biotechnology company based in Boulder, Colorado, founded in 2019. It specializes in drug screening services that assess drug action and toxicity by profiling drug effects in live cells using advanced biosensor technology. The company employs directed evolution to develop antibodies with programmable spatial fate in target cells, enhancing the precision of drug discovery. BioLoomics utilizes high-throughput multiplexed profiling to analyze biochemical events in mammalian cells, screening chemical libraries and complex mixtures to identify unique cellular responses. This innovative approach enables clients to improve the success rate and reduce the costs associated with drug development, making significant contributions to the field of synthetic biology and live-cell imaging.

Sonera Magnetics is engaged in developing advanced technology for high-performance, non-invasive brain-computer interfaces, aiming to enhance access to brain diagnostics. The company has created a magnetometer capable of measuring weak magnetic fields produced by brain activity, utilizing acoustically-driven ferromagnetic resonance. This technology operates at room temperature and in compact, portable formats, achieving sensitivity comparable to leading diagnostic tools that use superconducting sensors. Sonera Magnetics' systems are designed to facilitate the diagnosis and treatment of neurological disorders, such as epilepsy and dementia, by providing reliable brain imaging capabilities. Founded in 2018 in Berkeley, California, by Nishita Deka, Dominic Labanowski, and Sayeef Salahuddin, the company seeks to offer a practical and cost-effective solution for brain-computer interfacing.

Harmonic Discovery is a pharmaceutical company focused on developing innovative solutions for cancer treatment through its advanced drug platform. This platform integrates biological screening, medicinal chemistry, and computational chemistry to create kinase inhibitors that address cancer resistance mechanisms. By employing structural modeling and machine learning, Harmonic Discovery predicts potential clinical resistance mutations and optimizes the design of small molecule therapeutics. This approach aims to maintain essential therapeutic targets while minimizing harmful off-target interactions, thereby enhancing the effectiveness of cancer treatments for medical practitioners.

Monod Bio is a life sciences company headquartered in Seattle, Washington, specializing in the development of innovative biosensors for the detection of proteins, toxins, antibodies, and other analytes. Founded in 2021, the company leverages advances in computational protein engineering to create modular bio-sensing nanoswitches. These biosensors integrate binding, transduction, and amplification processes in a single step, allowing for rapid, sensitive, and cost-effective analytical assays. Monod Bio's technology aims to enhance the capabilities of the healthcare industry by providing advanced tools for biotechnology and medical applications.

Endpoint Health, Inc. is a precision immunology company focused on researching and developing therapies that enhance outcomes for patients with critical and immune-driven illnesses, including sepsis, acute respiratory distress syndrome, and COVID-19. Founded in 2018 and headquartered in Palo Alto, California, with additional offices in Detroit, Livonia, and Chicago, the company aims to overcome the limitations of traditional drug development by creating precision therapies tailored to individual patient needs. Utilizing its proprietary AI-powered platform, OMNAI, Endpoint Health identifies and matches high-potential therapies to patients most likely to benefit, ensuring personalized treatment that significantly improves health outcomes. The company is committed to delivering innovative solutions that address the complexities of autoimmune and inflammatory conditions.

Synthesis AI, Inc. is a data generation platform based in San Francisco, California, that specializes in synthetic data technology for computer vision applications. Founded in 2019, the company aims to enhance the capabilities of artificial intelligence by providing a solution that allows leading computer vision teams to create more effective models in a faster and more cost-efficient manner. Synthesis AI integrates innovative generative artificial intelligence models with cinematic visual effects to produce photorealistic and diverse images and videos, complete with accurate pixel-level labels. This technology enables clients to generate simulated and synthetic data, particularly for automotive applications, thereby accelerating the development of advanced AI systems.

Diligent Robotics Inc. is a company that specializes in the development and manufacturing of hospital service robots. Founded in 2017 and headquartered in Austin, Texas, the company has created Moxi, a robotic assistant designed to support clinical and nursing staff with logistical tasks in hospital settings. Moxi is equipped with advanced mobile manipulation, social intelligence, and human-guided learning capabilities, allowing it to collaborate effectively with human teams. By automating routine logistical duties, Moxi enables healthcare providers to focus more on direct patient care, thereby enhancing patient satisfaction, service quality, and safety in healthcare environments. The company also develops artificial intelligence-based software suites that allow its robots to adapt to and thrive in dynamic, semi-structured environments.

Fauna Bio Incorporated is a biotechnology company based in San Francisco, California, that focuses on developing a cross-mammal drug discovery platform aimed at treating human diseases. Established in 2018 by a team of scientists with expertise in non-model organisms, the company investigates the biological mechanisms found in hibernating and deep-diving animals to uncover potential therapeutic applications for conditions such as heart disease and neurodegenerative disorders. By leveraging data from a diverse range of species, Fauna Bio aims to identify novel drug targets and facilitate pre-clinical and early clinical testing for new therapeutics, ultimately helping humans recover from serious medical emergencies like trauma, heart attacks, and strokes.

Talus Bio is a biotechnology startup focused on drug discovery and development, particularly targeting challenging cancer transcription factors. The company employs an innovative approach that integrates functional proteomics, automated biology, and machine learning. Their MARMOT platform utilizes AI, advanced proteomics, synthetic chemistry, and computational biology to design and analyze drugs, proteins, and genomics. This platform is designed to advance drug development for gene regulation in oncology, aiming to create small-molecule therapies that can effectively control gene expression in cancer cells.

Shiok Meats is a Singapore-based company founded in 2018 that specializes in cellular aquaculture, focusing on the production of cell-based meats and seafood. By harvesting from cells rather than animals, the company aims to provide clean and healthy alternatives to traditional meat products. Its primary offerings include lab-cultured shrimp and other crustacean meats, which are designed to be animal-friendly, health-conscious, and environmentally sustainable. Shiok Meats strives to deliver products that retain the same taste, texture, and nutritional value as conventional seafood, thereby catering to consumers seeking healthier and more ethical food options.

Orchid is a reproductive technology startup founded in 2019 and headquartered in San Francisco, California. The company specializes in detecting rare genetic disorders through its preconception system, which analyzes the genomes of both partners to assess their genetic predispositions to various common diseases, such as heart disease, Alzheimer’s disease, and breast cancer. Orchid develops its results in collaboration with leading experts in reproductive medicine and genetics, ensuring high accuracy. The company offers a "Couple Report," which utilizes an at-home saliva test to evaluate each individual’s genetic profile and predict potential genetic risks for future children. In cases of elevated risk, Orchid provides actionable insights to assist couples in monitoring health markers, adjusting their diet, or considering procedures like in vitro fertilization.

Synthesis AI, Inc. is a data generation platform based in San Francisco, California, that specializes in synthetic data technology for computer vision applications. Founded in 2019, the company aims to enhance the capabilities of artificial intelligence by providing a solution that allows leading computer vision teams to create more effective models in a faster and more cost-efficient manner. Synthesis AI integrates innovative generative artificial intelligence models with cinematic visual effects to produce photorealistic and diverse images and videos, complete with accurate pixel-level labels. This technology enables clients to generate simulated and synthetic data, particularly for automotive applications, thereby accelerating the development of advanced AI systems.

Membio's single-use 0.2-10 L benchtop bioreactor system uses a proprietary design to provide a constant environment for cells at all scales. One technique will provide the same outcomes at all scales, whether at 0.2 L, 10 L, or anywhere in between. Fully automated single-use bioreactors designed by the business to enable cost-effective and scalable manufacture.

Diligent Robotics Inc. is a company that specializes in the development and manufacturing of hospital service robots. Founded in 2017 and headquartered in Austin, Texas, the company has created Moxi, a robotic assistant designed to support clinical and nursing staff with logistical tasks in hospital settings. Moxi is equipped with advanced mobile manipulation, social intelligence, and human-guided learning capabilities, allowing it to collaborate effectively with human teams. By automating routine logistical duties, Moxi enables healthcare providers to focus more on direct patient care, thereby enhancing patient satisfaction, service quality, and safety in healthcare environments. The company also develops artificial intelligence-based software suites that allow its robots to adapt to and thrive in dynamic, semi-structured environments.

A-Alpha Bio, Inc. is a biotechnology company specializing in synthetic biology and advanced quantitative measurement of protein interactions to facilitate drug development. Founded in 2017 and headquartered in Seattle, Washington, the company offers its proprietary AlphaSeq platform, which enables high-throughput mapping of protein-protein interactions. This technology allows for the simultaneous identification and quantification of interactions among thousands of protein pairs, streamlining the drug discovery process by aiding in the identification of potential drug targets and enhancing the understanding of disease mechanisms. By providing biologics and molecular glue discovery and optimization services, A-Alpha Bio supports pharmaceutical companies in optimizing binding and specificity to multiple target proteins. The team comprises synthetic biologists, structural biologists, and next-generation sequencing experts dedicated to overcoming challenges in the drug development process.

Shiok Meats is a Singapore-based company founded in 2018 that specializes in cellular aquaculture, focusing on the production of cell-based meats and seafood. By harvesting from cells rather than animals, the company aims to provide clean and healthy alternatives to traditional meat products. Its primary offerings include lab-cultured shrimp and other crustacean meats, which are designed to be animal-friendly, health-conscious, and environmentally sustainable. Shiok Meats strives to deliver products that retain the same taste, texture, and nutritional value as conventional seafood, thereby catering to consumers seeking healthier and more ethical food options.

Fauna Bio Incorporated is a biotechnology company based in San Francisco, California, that focuses on developing a cross-mammal drug discovery platform aimed at treating human diseases. Established in 2018 by a team of scientists with expertise in non-model organisms, the company investigates the biological mechanisms found in hibernating and deep-diving animals to uncover potential therapeutic applications for conditions such as heart disease and neurodegenerative disorders. By leveraging data from a diverse range of species, Fauna Bio aims to identify novel drug targets and facilitate pre-clinical and early clinical testing for new therapeutics, ultimately helping humans recover from serious medical emergencies like trauma, heart attacks, and strokes.

Shiok Meats is a Singapore-based company founded in 2018 that specializes in cellular aquaculture, focusing on the production of cell-based meats and seafood. By harvesting from cells rather than animals, the company aims to provide clean and healthy alternatives to traditional meat products. Its primary offerings include lab-cultured shrimp and other crustacean meats, which are designed to be animal-friendly, health-conscious, and environmentally sustainable. Shiok Meats strives to deliver products that retain the same taste, texture, and nutritional value as conventional seafood, thereby catering to consumers seeking healthier and more ethical food options.

Diligent Robotics Inc. is a company that specializes in the development and manufacturing of hospital service robots. Founded in 2017 and headquartered in Austin, Texas, the company has created Moxi, a robotic assistant designed to support clinical and nursing staff with logistical tasks in hospital settings. Moxi is equipped with advanced mobile manipulation, social intelligence, and human-guided learning capabilities, allowing it to collaborate effectively with human teams. By automating routine logistical duties, Moxi enables healthcare providers to focus more on direct patient care, thereby enhancing patient satisfaction, service quality, and safety in healthcare environments. The company also develops artificial intelligence-based software suites that allow its robots to adapt to and thrive in dynamic, semi-structured environments.